NAD(P)H Dehydrogenase (Quinone)
"NAD(P)H Dehydrogenase (Quinone)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A flavoprotein that reversibly catalyzes the oxidation of NADH or NADPH by various quinones and oxidation-reduction dyes. The enzyme is inhibited by dicoumarol, capsaicin, and caffeine.
| Descriptor ID |
D016660
|
| MeSH Number(s) |
D08.811.682.608.800.500
|
| Concept/Terms |
NAD(P)H Dehydrogenase (Quinone)- NAD(P)H Dehydrogenase (Quinone)
- Quinone Reductase
- Reductase, Quinone
- Phylloquinone Reductase
- Reductase, Phylloquinone
- DT Diaphorase
- Diaphorase, DT
- Menadione Reductase
- Reductase, Menadione
|
Below are MeSH descriptors whose meaning is more general than "NAD(P)H Dehydrogenase (Quinone)".
Below are MeSH descriptors whose meaning is more specific than "NAD(P)H Dehydrogenase (Quinone)".
This graph shows the total number of publications written about "NAD(P)H Dehydrogenase (Quinone)" by people in this website by year, and whether "NAD(P)H Dehydrogenase (Quinone)" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "NAD(P)H Dehydrogenase (Quinone)" by people in Profiles.
-
Aurothioglucose does not improve alveolarization or elicit sustained Nrf2 activation in C57BL/6 models of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2018 05 01; 314(5):L736-L742.
-
Role of migratory inhibition factor in age-related susceptibility to radiation lung injury via NF-E2-related factor-2 and antioxidant regulation. Am J Respir Cell Mol Biol. 2013 Aug; 49(2):269-78.
-
NQO1 activation regulates angiotensin-converting enzyme shedding in spontaneously hypertensive rats. Cardiovasc Res. 2013 Sep 01; 99(4):743-50.
-
Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics. 2012 Dec; 13(16):1925-35.
-
Interactions between glucocorticoid treatment and cis-regulatory polymorphisms contribute to cellular response phenotypes. PLoS Genet. 2011 Jul; 7(7):e1002162.
-
Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles. Breast Cancer Res Treat. 2012 Feb; 132(1):175-87.
-
Chromosome band 16q22-linked familial AML: exclusion of candidate genes, and possible disease risk modification by NQO1 polymorphisms. Genes Chromosomes Cancer. 2004 Nov; 41(3):278-82.
-
Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood. 1999 Jul 15; 94(2):803-7.
-
Studies on three reductases which have polycyclic aromatic hydrocarbon quinones as substrates. Arch Biochem Biophys. 1993 Jun; 303(2):394-401.
-
A growth arrest-specific (gas) gene codes for a membrane protein. Mol Cell Biol. 1990 Jun; 10(6):2924-30.